Metabolomics Unlocks New Clues to Why We Lose Hearing as We Age
A systematic review reveals how metabolic pathways like amino acid and lipid metabolism drive acquired hearing loss — and points to promising new biomarkers.
Summary
Researchers at Peking Union Medical College reviewed how metabolomics — the large-scale study of small molecules in biological systems — is being applied to acquired hearing loss, including age-related, noise-induced, and sudden sensorineural types. By analyzing metabolites in inner ear tissue, perilymph, and plasma, studies have identified disrupted pathways including amino acid metabolism, lipid metabolism, purine and pyrimidine metabolism, and autophagy. Biomarkers such as sphingosine show early promise for predicting diagnosis and prognosis. The authors call for standardized study designs, larger sample sizes, and integration of metabolomics with other omics technologies to accelerate clinical translation and novel treatment development.
Detailed Summary
Hearing loss affects hundreds of millions of people globally and is increasingly recognized as a risk factor for cognitive decline and reduced quality of life in aging populations. Understanding the biological mechanisms behind acquired hearing loss has been hindered by the complexity of the inner ear environment. Metabolomics — which profiles the full set of small-molecule metabolites in biological samples — offers a powerful lens for capturing how genetic predispositions and environmental exposures converge to damage hearing.
This systematic review from a leading Chinese medical institution synthesizes the latest metabolomics research applied to three major forms of acquired hearing loss: age-related hearing loss (presbycusis), noise-induced hearing loss, and sudden sensorineural hearing loss. The authors examined studies using samples from inner ear tissues, perilymph fluid, and peripheral blood plasma to map disrupted metabolic signatures.
Key findings point to consistent dysregulation across several metabolic pathways. Amino acid metabolism, lipid metabolism, and purine/pyrimidine metabolism appear repeatedly implicated across hearing loss subtypes. Autophagy-related metabolic changes also emerge as a recurring theme, suggesting cellular recycling dysfunction may contribute to cochlear cell death. Sphingosine, a lipid-derived signaling molecule, stood out as a particularly promising candidate biomarker for both diagnosis and prognosis.
For longevity-focused readers, these findings are significant: age-related hearing loss shares metabolic hallmarks with other aging processes including mitochondrial dysfunction, oxidative stress, and impaired cellular maintenance — all central to longevity biology. Metabolomics may help identify individuals at early risk and reveal druggable targets.
The authors caution that current studies are limited by small sample sizes, inconsistent methodologies, and a lack of clinical validation. They advocate for multi-omics integration and larger, standardized trials to move promising biomarkers toward clinical use.
Key Findings
- Amino acid, lipid, and purine/pyrimidine metabolism pathways are consistently disrupted across acquired hearing loss types.
- Sphingosine shows potential as a diagnostic and prognostic biomarker for acquired hearing loss.
- Autophagy-related metabolic changes may drive cochlear cell death in multiple hearing loss subtypes.
- Metabolomics applied to inner ear tissue, perilymph, and plasma reveals distinct and overlapping metabolic signatures.
- Standardizing experimental design and expanding sample sizes are critical next steps for clinical translation.
Methodology
This is a systematic review synthesizing published metabolomics studies on acquired hearing loss, including age-related, noise-induced, and sudden sensorineural subtypes. Biological samples analyzed across reviewed studies include inner ear tissues, perilymph, and plasma. The review focuses on differentially expressed metabolites and pathway enrichment analyses from existing human and animal studies.
Study Limitations
The review is constrained by the small sample sizes and heterogeneous methodologies of the underlying studies, limiting comparability and generalizability. Most findings remain in the discovery phase without prospective clinical validation of proposed biomarkers. The abstract-only access means specific effect sizes, study counts, and inclusion/exclusion criteria cannot be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.